Wegovy weight loss injections: what the evidence and real-world experience show

What do the trial results for Wegovy injections show?

The clearest place to start is the trial data, because it is the foundation everything else sits on. The STEP 1 study, published in the New England Journal of Medicine, followed nearly 2,000 adults with obesity over 68 weeks. Participants taking semaglutide 2.4mg alongside lifestyle support lost an average of around 15% of their body weight. Roughly a third lost more than 20%. Those are meaningful numbers — not a minor nudge.

More recently, a higher maintenance dose of 7.2mg received MHRA approval in January 2026, with a dedicated single-dose pen cleared in April 2026. Early data for 7.2mg reported average losses of around 20.7% over 72 weeks, narrowing the gap with tirzepatide. If you want a fuller picture of how Wegovy injections work and what the licensed doses look like, that page covers the mechanism in more depth.

Trial results are averages, though. Some people lose more, some less, and a small proportion lose less than 5%, which is why NICE guidance notes that if less than 5% weight is lost after six months at the maintenance dose, continuing treatment should be reviewed. Weight is shaped by biology, hormones, gut microbiome and dozens of other variables, not just effort. The medicine works with those systems, not instead of them.

What do people commonly report once they start using the Wegovy pen?

The experience of actually using the injection is something many people are curious about before they begin. The pen itself is pre-filled and pre-set; there is no need to draw up a dose or handle a vial. Injection sites rotate between the abdomen, thigh and upper arm, and the needle is fine. Most people find the administration process unremarkable after the first use.

What people notice more is the appetite change. Described most often as a quietening of food noise (that background pull towards eating even when not hungry) it tends to become noticeable in the first two to four weeks. Portions feel satisfying at a smaller size. The drive to pick between meals reduces. For detailed practical guidance on using the Wegovy pen correctly, the Patient Information Leaflet that comes with your prescription is the authoritative reference.

Side effects are reported honestly in the trial data: gastrointestinal symptoms are the most common, with nausea leading the list, followed by constipation, diarrhoea, bloating and indigestion. For most people these are mild to moderate and settle over a few weeks, particularly if doses are increased slowly. Staying well hydrated and avoiding very fatty or rich food during the adjustment period helps. Fatigue and mild headaches are also reported, especially in the early weeks. If you are weighing up semaglutide more broadly, including how its side-effect profile compares across uses, there is further reading available.

Are there symptoms that should prompt medical attention?

This deserves its own section, because it matters. The NHS medicines guidance for semaglutide lists the signs that need prompt attention: severe or persistent stomach pain, particularly if it radiates towards the back (which can be a sign of pancreatitis and warrants urgent medical assessment), signs of an allergic reaction such as swelling of the face or throat, or symptoms of gallbladder problems including pain in the upper right abdomen. Dehydration from prolonged vomiting or diarrhoea is also worth taking seriously, it can affect kidney function.

It is worth knowing that patients and healthcare professionals can report suspected side effects to the MHRA through the Yellow Card scheme. This reporting is how the safety profile of newer medicines gets refined over time, and it is genuinely useful to the regulator. The pancreatitis signal in particular was the subject of an MHRA Drug Safety Update in January 2026, reinforcing the guidance that severe abdominal pain during GLP-1 treatment should not be waited out.

Most people on Wegovy do not experience these serious effects. But knowing the warning signs is part of using any prescription medicine responsibly, and a good prescriber will go through them with you at the outset.

What context is useful for thinking about cost and access?

Many people reading about Wegovy also want to know whether it is available on the NHS and what private treatment costs. The short answer on NHS access: Wegovy is recommended by NICE for use within specialist weight management services, but waiting lists are commonly long and eligibility criteria are strict. For most people exploring private options, the private weight management route is the practical alternative.

On cost, Eli Lilly's September 2025 price adjustment reshaped the market for tirzepatide, and Wegovy private prices vary by dose and provider. A breakdown of what to look for in any quoted price (and what is often not included) is covered on the treatment and pricing page. If you are considering Wegovy weight loss injections and want to understand how the treatment is structured, including dosing schedules and eligibility, that page goes into the detail. For a nuanced comparison of how semaglutide-based treatments differ from each other, including Ozempic (which is licensed for type 2 diabetes, not weight loss), that page unpacks the distinctions clearly.

At nume, at nume, every consultation is reviewed personally by a GPhC-registered Independent Prescriber, not passed through automated screening. If you have questions before starting, the FAQs cover the most common ones, and the team is reachable through the contact page seven days a week. When you feel ready to take the next step, you can also read what others have said about their experience with Wegovy injections before speaking to our prescribers, which is straightforward and free.